Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Mallinckrodt
Baxter
Merck
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,856,336

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,856,336 protect, and when does it expire?

Patent 5,856,336 protects LIVALO and is included in one NDA.

Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ten patent family members in nine countries.

Summary for Patent: 5,856,336
Title: Quinoline type mevalonolactones
Abstract:A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.
Inventor(s): Fujikawa; Yoshihiro (Funabashi, JP), Suzuki; Mikio (Funabashi, JP), Iwasaki; Hiroshi (Funabashi, JP), Sakashita; Mitsuaki (Shiraoka-machi, JP), Kitahara; Masaki (Shiraoka-machi, JP)
Assignee: Nissan Chemical Industries Ltd. (Tokyo, JP)
Application Number:07/883,398
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,856,336
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,856,336

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,856,336

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan62-207224Aug 20, 1987
Japan63-15585Jan 26, 1988
Japan63-193606Aug 03, 1988

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.